Fig. 1: Schematic of R848@M2pep-MPsAFP as an efficient therapeutic strategy to potentiate anti-PD-1 antibody therapy in HCC. | Nature Communications

Fig. 1: Schematic of R848@M2pep-MPsAFP as an efficient therapeutic strategy to potentiate anti-PD-1 antibody therapy in HCC.

From: Cell microparticles loaded with tumor antigen and resiquimod reprogram tumor-associated macrophages and promote stem-like CD8+ T cells to boost anti-PD-1 therapy

Fig. 1

a Schematic illustration of the preparation of R848@M2pep-MPsAFP. R848@M2pep-MPsAFP were obtained by loading R848 to M2pep-conjugated MPs derived from AFP-overexpressing RAW264.7 cells by lentivirus transduction. b Schematic illustration of R848@M2pep-MPsAFP to boost anti-PD-1 antibody therapy in HCC. R848@M2pep-MPsAFP targeted and reprogrammed M2-like TAMs into M1-like phenotype, followed by presenting AFP antigen to activate antigen-specific CD8+ T cell for tumor control and promote stem-like CD8+ T cell proliferation and differentiation. Combination with anti-PD-1 antibody generated strong antitumor immune memory and induced abundant stem-like CD8+ T cell proliferation and differentiation to terminally exhausted CD8+ T cells for long-term immune surveillance.

Back to article page